Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.
Korsana Biosciences has raised $380.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2026.
Korsana Biosciences's investors include RA Capital Management, General Atlantic, Wellington Management, J.P. Morgan Asset Management, Foresite Capital.
Korsana Biosciences is headquartered in Waltham, United States.
Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases including Alzheimer’s.
Korsana Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Korsana Biosciences — Funding & Investors." VCBacked, September 8, 2026, https://www.vcbacked.co/company/korsana-biosciences. Accessed October 22, 2026.
VCBacked. (2026). Korsana Biosciences — Funding & Investors. Retrieved October 22, 2026, from https://www.vcbacked.co/company/korsana-biosciences
{{cite web |title=Korsana Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/korsana-biosciences |website=VCBacked |access-date=October 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated